An Open-label, Multicenter Phase II Clinical Trial of SHR-1701 With or Without Chemotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Retlirafusp alfa (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 08 Jul 2024 Results published in the Cancer Cell.
- 04 Jun 2024 Primary endpoint (EFS) has been met.
- 04 Jun 2024 Primary endpoint (ORR) has been met.